article thumbnail

STAT+: Drug may make chemotherapies less effective in cancer patients with obesity — but many doctors are in the dark

STAT

This means chemotherapies may be less effective when interacting with the medicine, but some clinicians, and their patients, are unaware of that possibility. At issue is a medicine called posaconazole that was approved in 2006 in the U.S. And the company has refused to update the language. but is now also sold by generic companies.

article thumbnail

Opinion: What the public might learn from Kate Middleton, the latest ‘famous patient’

STAT

By the time I wrote my book , “When Illness Goes Public: Celebrity Patients and How We Look at Medicine” in 2006, there were hundreds of stories of famous patients I could have told.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

STAT+: Pharmalittle: More than 9 in 10 pharmacy techs report drug shortages; Yale and VA strike deal over ketamine patent royalties

STAT

Krystal, who worked for both Yale and the VA at the time, and his co-inventors applied for patents with VA funding starting in 2006 for a ketamine nasal spray to treat depression and suicidal ideation.

article thumbnail

Country focus: China & APAC’s growing medical needs bring opportunities and challenges

pharmaphorum

Chemotherapy still accounted for 72.6% Chemotherapy still plays a significant role in oncology treatment, accounting for 72.6% While all of the top ten best-selling oncology drugs in the US in 2019 were innovative therapies, four out of the top ten best-selling oncology drugs in China were for conventional chemotherapy. “In

article thumbnail

Solving the taxing problems of taxanes?

European Pharmaceutical Review

Despite advances with targeted and immuno-oncology therapies, chemotherapies remain a cornerstone of cancer treatment for many tumour types – a reflection of their significant anti?tumour While highly effective, taxanes also exhibit several of the typical limitations associated with systemic chemotherapies. tumour effects. References.

article thumbnail

J&J bulks up in bispecifics with $1.3bn Xencor alliance

pharmaphorum

Xencor has previously partnered with MorphoSys and Incyte to test plamotamab in combination with their CD19-targeted antibody Monjuvi (tafasitamab) – plus Bristol-Myers Squibb’s Revlimid (lenalidomide) – as a chemotherapy-free strategy for relapsed or refractory diffuse large B-cell lymphoma (DLBCL), an aggressive type of NHL.

article thumbnail

Laurent Bonnac, PhD

Blog: Ask a Student Pharmacist

Antimicrobial agents and chemotherapy. Antimicrobial agents and chemotherapy. Antiviral chemistry & chemotherapy. 2006; Chapter 13:Unit 13.4. Rawson JM, Daly MB, Xie J, Clouser CL, Landman SR, Reilly CS, Bonnac Laurent , Kim B, Patterson SE, Mansky LM. 2016; 60(4):2318-25. Dual anti-HIV mechanism of clofarabine.